/Boston%20Scientific%20Corp_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $144.2 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets innovative medical devices used in various interventional medical specialties worldwide. It operates through two main segments: MedSurg and Cardiovascular, offering advanced solutions for diagnosing and treating complex conditions across gastrointestinal, urological, neurological, and cardiovascular care.
The Marlborough, Massachusetts-based company is slated to announce its fiscal Q3 2025 earnings results before the market opens on Wednesday, Oct. 22. Ahead of the event, analysts expect Boston Scientific to report an adjusted EPS of $0.71, up 12.7% from $0.63 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarterly reports.